Microarray Analysis of Scalp Biopsies After Minoxidil Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01309191|
Recruitment Status : Completed
First Posted : March 7, 2011
Last Update Posted : February 27, 2014
|Condition or disease||Intervention/treatment||Phase|
|Androgenetic Alopecia||Drug: Minoxidil Other: Placebo||Not Applicable|
The most common type of hair loss is androgenetic alopecia (AGA), also known as male pattern balding, or hereditary thinning. In AGA, there is a gradual transformation of large terminal hair follicles to miniaturized ones under the influence of circulating androgens that produce smaller and finer hairs with a shorter anagen cycle. This transformation, which can be seen as early as the prepubescent years, occurs only in certain regions of the scalp: the frontal hairline, top and vertex scalp. The temporo-occipital region is largely unaffected even in those with extensive balding.
The first drug to be approved for the FDA for the treatment of AGA was topical minoxidil solution (TMS). Despite its successful use, the mechanism of action of TMS is not well understood. Minoxidil is a potent vasodilator and potassium channel opener, but its mechanism of action in promoting hair regrowth appears to be independent of its vasodilation properties. Improved knowledge of the changes in gene expression associated with AGA before and after treatment with TMS and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of TMS. Furthermore, there is potential for identification of those patients who would best respond to or benefit from treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||April 2012|
Patients received Minoxidil (same strength as sold over the counter) twice a day for 8 weeks.
Over the counter Rogaine, twice a day for 8 weeks
Other Name: Rogaine
Placebo Comparator: Placebo
- Analysis of change in gene expression before and after topical minoxidil application [ Time Frame: at baseline and after 8 weeks of treatment ]
- Differences ing ene expression in two different regions of the scalp, frontal and vertex. [ Time Frame: Baseline and after 8 weeks of treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01309191
|United States, Ohio|
|Skin Study Center, UH Case Medical Center|
|Cleveland, Ohio, United States, 44106|
|Principal Investigator:||Pratima Karnik, Ph.D.||UH Case Medical Center|